DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Should You Buy?

DBV Technologies S.A. (NASDAQ:DBVT) gapped up before the market opened on Thursday . The stock had previously closed at $20.00, but opened at $20.85. DBV Technologies shares last traded at $19.5350, with a volume of 161,540 shares.

Analyst Ratings Changes

DBVT has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $20.00 price target (up from $16.00) on shares of DBV Technologies in a research report on Wednesday, October 29th. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. Weiss Ratings restated a “sell (d-)” rating on shares of DBV Technologies in a research note on Monday. Zacks Research raised DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Finally, Guggenheim started coverage on shares of DBV Technologies in a research report on Wednesday, December 3rd. They set a “buy” rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, DBV Technologies has a consensus rating of “Moderate Buy” and an average price target of $20.81.

DBV Technologies Price Performance

The company has a fifty day moving average price of $14.55 and a two-hundred day moving average price of $11.29. The company has a market capitalization of $753.10 million, a P/E ratio of -3.75 and a beta of -1.10.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Vivo Capital LLC bought a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,659,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of DBV Technologies in the 2nd quarter worth approximately $9,659,000. MPM Bioimpact LLC bought a new stake in shares of DBV Technologies in the 2nd quarter valued at $9,649,000. Octagon Capital Advisors LP acquired a new stake in shares of DBV Technologies during the second quarter worth $9,315,000. Finally, Millennium Management LLC raised its stake in DBV Technologies by 26.1% during the third quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock worth $3,379,000 after buying an additional 69,849 shares during the last quarter. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.